Cadrenal Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Cadrenal Therapeutics Inc CVKD.OQ reported a quarterly adjusted loss of $1.87​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-2.25. The mean expectation of three analysts for the quarter was for a loss of $1.60 per share. Wall Street expected results to range from $-2.07 to $-1.24 per share.

• Reported revenue was zero​; analysts expected zero.

• Cadrenal Therapeutics Inc's reported EPS for the quarter was a loss of $1.87​.

• The company reported a quarterly loss of $3.67 million.

• Cadrenal Therapeutics Inc shares had fallen by 7.5% this quarter and lost 23.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 17.4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Cadrenal Therapeutics Inc is $32.00, about 65.2% above its last closing price of $11.15

This summary was machine generated from LSEG data August 11 at 12:48 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)